Beclometasone/formoterol - Chiesi Farmaceutici
Alternative Names: BDP/FF - Chiesi Farmaceutici; Beclometasone dipropionate/formoterol fumarate dihydrate; Beclomethasone/formoterol; CHF 1535 35/4 NEXTHALER®; CHF-1535; Combair; Formodual; Formoterol/beclometasone; Fostair; Fostair NEXThaler; Foster; Foster Nexthaler; Foster Spray; Fostex; Fostex NEXThaler; Innovair; Innovair NEXThaler; Inuvair; Inuver; Inuxair; Kantos; Kantos Master; Kantos NEXThalerLatest Information Update: 22 Nov 2024
Price :
$50 *
At a glance
- Originator Chiesi Farmaceutici
- Developer Chiesi Farmaceutici; Chiesi USA
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Chlorinated steroids; Corticosteroids; Ethanolamines; Pregnadienetriols; Small molecules; Vascular disorder therapies
- Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 25 Jun 2024 Chiesi Farmaceutici completes phase III FORCE2 trial in Asthma (Inhalation) in USA (NCT05292586)
- 19 May 2023 Efficacy and adverse event data from the phase III FORTUNE trial for Asthma presented at the 119th International Conference of the American Thoracic Society (ATS-2023)
- 01 Feb 2023 Chiesi Farmaceutici completes the phase III FEEL trial for Asthma (In adults, In the elderly) in Italy (Inhalation, Solution) (NCT04886999) (EudraCT2021-001449-11)